A Phase 2 interventional study of rLP2086 in Meningitis, Meningococcal, Serogroup B, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-20.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 6th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:
University Ghent · Sites in Belgium
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 4
First in 2006; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 250 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Meningitis, Meningococcal by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 5 (50%) have results posted.
Among the 10 studies in Meningitis, Meningococcal by Pfizer, this one is the only one that started in 2013, is one of 4 in phase 2, and was the 10th registered.
Pfizer’s Meningitis, Meningococcal studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Meningitis, Meningococcal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086 vaccine in laboratory workers ≥18 to ≤65 years of age administered on a Month 0, 2, and 6 schedule. The study will recruit laboratory personnel (inclusive of Pfizer staff) who work directly with pathogenic Neisseria meningitidis in the context of the bivalent rLP2086 vaccine development program. The study will provide descriptive safety and immunogenicity data following vaccination of these individuals with bivalent rLP2086 vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: rLP2086
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)
Time frame: 1 month after vaccination 3
Percentage of Participants With at Least One Adverse Event (AE)
Time frame: Vaccination 1 up to 1 month after Vaccination 3
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ
Time frame: 1 month after vaccination (Vac) 1, 2, Immediately prior to vaccination 3
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined
Time frame: 1 month after vaccination 3
Number of Participants With 4-fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level
Time frame: 1 month after vaccination 3
| Milestone | rLP2086 |
|---|---|
| Started | 13 |
| Completed | 7 |
| Not completed | 6 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 3 |
| participants | rLP2086 |
|---|---|
| PMB80 [A22] 1:16 (N=6) | 6 (54.1 to 100.0) |
| PMB2001 [A56] 1:8 (N=5) | 5 (47.8 to 100.0) |
| PMB2948 [B24] 1:8 (N=6) | 6 (54.1 to 100) |
| PMB2707 [B44] 1:8 (N=6) | 3 (11.8 to 88.2) |
| percentage of participants | rLP2086 |
|---|---|
| Percentage of Participants With at Least One Adverse Event (AE) | 46.2 |
| participants | rLP2086 |
|---|---|
| 1 month after Vac 1: PMB80 [A22] 1:16 (N=6) | 3 (11.8 to 88.2) |
| 1 month after Vac 2: PMB80 [A22] 1:16 (N=5) | 3 (22.3 to 95.7) |
| Immediately prior to Vac 3: PMB80 [A22] 1:16 (N=6) | 4 (54.1 to 100.0) |
| 1 month after Vac 1: PMB2001 [A56] 1:8 (N=6) | 4 (4.3 to 77.7) |
| 1 month after Vac 2: PMB2001 [A56] 1:8 (N=6) | 6 |
| Immediately prior to Vac 3: PMB2001 [A56] 1:8(N=6) | 4 |
| 1 month after Vac 1: PMB2948 [B24] 1:8 (N=6) | 6 |
| 1 month after Vac 2: PMB2948 [B24] 1:8 (N=6) | 6 |
| Immediately prior to Vac 3: PMB2948 [B24] 1:8(N=6) | 5 |
| 1 month after Vac 1: PMB2707 [B44] 1:8 (N=6) | 2 |
| 1 month after Vac 2: PMB2707 [B44] 1:8 (N=6) | 3 |
| Immediately prior to Vac 3: PMB2707 [B44] 1:8(N=6) | 2 |
| participants | rLP2086 |
|---|---|
| Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined | 3 (14.7 to 94.7) |
| participants | rLP2086 |
|---|---|
| PMB80 [A22] (N=6) | 5 (35.9 to 99.6) |
| PMB2001 [A56] (N=5) | 5 (47.8 to 100.0) |
| PMB2948 [B24] (N=6) | 4 (22.3 to 95.7) |
| PMB2707 [B44] (N=6) | 3 (11.8 to 88.2) |
Collected over AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086). SAE reported from Vaccination 1 to 6 months after last administration of investigational product (bivalent rLP2086). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rLP2086 | — | 0/13 (0%) | 6/13 (46.2%) |
| Event | rLP2086 |
|---|---|
| Gouty arthritisMusculoskeletal and connective tissue disorders | 1/7 |
| Eye PainEye disorders | 1/13 |
| Respiratory tract infection viralInfections and infestations | 1/13 |
| Urinary tract infectionInfections and infestations | 1/13 |
| Upper respiratory tract infectionInfections and infestations | 1/13 |
| PresyncopeNervous system disorders | 1/13 |
| ChillsGeneral disorders | 1/13 |
| Age, Customized(participants) | rLP2086 |
|---|---|
| 18- 40 years | 5 |
| Greater than (>) 40 years | 8 |
| Sex: Female, Male(Participants) | rLP2086 |
|---|---|
| Female | 9 |
| Male | 4 |
The record gives a start of Feb 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine